Chemokine Therapeutics Corp.

Authorities okay launch of phase Ib/II human clinical trial for anticancer drug CTCE-9908

Published in Oncology Business Week, March 12th, 2006

Chemokine Therapeutics Corp. (CHKT), a biotechnology company developing drugs in the field of chemokines, announced that it has received approval from Health Canada to initiate a phase Ib/II clinical trial using CTCE-9908, a chemokine CXCR4 antagonist.

With this notice, the company is now in a position to initiate the clinical trial. The company plans to test the drug in up to 30 patients with late-stage cancers to evaluate safety as well as early efficacy. The trial is designed to study a mixed group of tumors that will include the most common cancers such as ovarian, lung, and breast.

Chemokine expects to expand its CTCE-9908 clinical program with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2006-03-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry